Keywords
Pregnancy
Therapeutics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objetivo: Relatar el caso de una paciente diagnosticada de enfermedad de Crohn que manifiesta el deseo de quedarse embarazada y que evoluciona con el nacimiento de un feto sano, revisando científicamente las posibles complicaciones materno-fetales y sus interrelaciones. Detalle del caso: Paciente femenina, de veintidós años, con diagnóstico reciente de enfermedad de Crohn y después de tres años de tratamiento regular con gastroenterólogo, manifiesta deseo de quedar embarazada. A la edad de veintiocho años queda embarazada, usando aminosalicilatos, corticosteroides e inmunobiológicos. Durante el transcurso del embarazo presenta recaída de la enfermedad y después del nacimiento a término de un niño sano, presenta complicaciones en el puerperio. Consideraciones finales: La alta prevalencia de enfermedades inflamatorias intestinales en mujeres puede ser un obstáculo para el deseo de embarazo. Sin embargo, actualmente existen varios estudios que demuestran la existencia de terapias efectivas y seguras para el binomio madre-feto, como el uso de aminosalicilatos e inmunomoduladores. Es necesario hacer un seguimiento con un gastroenterólogo y un equipo multidisciplinario para individualizar cada caso e institución de tratamiento adecuado.
References
BRAGA, A, et al. Doença inflamatória intestinal - Doença de Crohn e gravidez: relato de caso. Rev. Bras. Ginecol. Obstet., 2011; 33(4).
CARVALHO, GF. Leptina sérica, calprotectina fecal e composição corporal em pacientes com Doença de Crohn. Dissertação (Mestrado em Ciências Farmacêuticas) - Faculdade de Farmácia, Universidade Federal de Minas Gerais. Belo Horizonte, 2022; 90.
CASADO MPB e SIERRA, GMD. Abordaje terapéutico de la enfermedad de Crohn en embarazo y obesidad. Rev. OFIL·ILAPHAR, Madrid, 2022; 32(3): 307-308.
CORREIA L, et al. Doença Inflamatória Intestinal e Gravidez – relatos de dois casos de uso de infliximab e revisão da literatura. GED, 2010; 29(1): 23-28.
FERRERO S e RAGNI N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet., 2004; 270(2): 79-85.
HART A, et al. Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn‘s disease who became pregnant: A post hoc analysis. United European Gastroenterol J., 2022; 10(5): 485-495.
HELLSING C, et al. Delivery mode and risk of gastrointestinal disease in the offspring. Acta Obstet Gynecol Scand., 2022; 101(10): 1146-1152.
KOTZE P, et al. Reindução da Remissão Clínica com Adalimumabe após Interrupção do Tratamento: Uma Alternativa no Manejo da Doença de Crohn. Rev bras Coloproct Abril/Junho, 2010; 30(2): 135-140.
LE COSQUER G, et al. A Rare Pregnancy-related Complication of Crohn‘s Disease: Diagnosis and Treatment. Diagnosis and Treatment. Gastroenterology, 2022; 163(3): 586-587.
PRENTICE R, et al. Preconception, antenatal and postpartum management of inflammatory bowel disease. Aust J Gen Pract., 2022; 51(10): 747-753.
KUMAR, V, et al; ASTER, JC.; ABBAS, AK. ROBBINS E COTRAN. Patologia-Bases Patológicas das Doenças. GEN Guanabara Koogan; 2023; 10: 1447-1455.
ROLDI N, et al. , Tratamento da doença de Crohn durante a gravidez. Rev Soc Bras Clin Med., 2017; 15(1): 68-72.
RONCHETTI C, et al. Inflammatory Bowel Disease and Reproductive Health: From Fertility to Pregnancy-A Narrative Review. Nutrients, 2022; 14(8): 1591.
SCHULZE H, et al. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther, 2014; 40: 991-1008.
SOBRADO LF, et al. Fournier‘s Gangrene During Pregnancy in a Patient with Crohn‘s Disease. PubMed, [s. l.]. Rep., 2022; 23: e934942.
STROIE, T, udor et al. Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Clinical Remission: What Should We Look For?. 2022; 58(4): 486.
TRUTA B. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place. World J Gastroenterol., 2022; 28(13): 1380-1383.
WALSHAM NE e SHERWOOD RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol., 2016; 9: 21-9.
WANG G, et al. A Novel Decision Aid Improves Quality of Reproductive Decision-Making and Pregnancy Knowledge for Women with Inflammatory Bowel Disease. Dig Dis Sci., 2022; 67(9): 4303-4314.
YARUR A e KANE SV. Update on pregnancy and breastfeeding in the era of biologics. Dig Liver Dis., 2013; 45(10): 787-794.
WU RY, et al. Elevated IL-6 and IL-22 in Early Pregnancy Are Associated with Worse Disease Course in Women with Inflammatory Bowel Disease. Int J Mol Sci., 2022; 23(18): 10281.
ZALTMAN C, et al. Diretrizes de doença de Crohn. International journal of inflammatory bowel disease, 2018; 4(1): 28-37.